tirzepatide surmount-1 weight loss percent 72 weeks results as Compared with Semaglutide for the Treatment of Obesity Analysis of Tirzepatide Acquisition Costs
Description
It's unique to retatrutide because no other approved obesity medication activates glucagon receptors
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Researchs GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and published earlier this year in JAMA Internal Medicine
Ahmann AJ, Capehorn M, Charpentier G, et al
Every missed weekly injection represents 14% of monthly treatment absent
Proper landmarking prevents this
